Consider an illustrative case: a 62-year-old man has had chest pressure and diaphoresis for 45 minutes. His ECG shows 2-mm J-point ST elevation in V2–V4, but the first high-sensitivity troponin is within the reference range. Assuming the tracing is technically adequate and the elevations are new or presumed new, should the team wait for a repeat result before activating reperfusion? No—when the ECG and clinical presentation establish a STEMI pattern.
The key distinction is between an urgent ECG-based management decision and the later biomarker-supported diagnosis of myocardial infarction. Troponin matters; it just does not have to be positive before reperfusion begins.
Read the ECG as an action signal
For new or presumed-new J-point ST elevation, the 2025 U.S. acute coronary syndrome guideline uses a threshold of at least 1 mm in two anatomically contiguous leads, except V2–V3, which have sex- and age-specific thresholds. In those leads, the threshold is at least 2 mm for men aged 40 or older, 2.5 mm for men younger than 40, and 1.5 mm for women. In this 62-year-old man, the stated elevations meet the V2–V3 threshold, assuming a technically adequate tracing and new or presumed-new changes.
A compatible ischemic presentation plus a qualifying ECG pattern should prompt rapid activation of the STEMI reperfusion pathway. The ECG does not map the coronary anatomy or prove that myocardial necrosis has already occurred. It identifies a dangerous pattern for which delay can cost myocardium.
That is why “STEMI” is useful as an immediate triage and treatment category, even before a full biomarker result is available. The decision is not “Has troponin confirmed infarction?” but “Does this presentation require urgent reperfusion?”
Why the first troponin can be normal
Troponin indicates myocardial injury, not ischemia alone. In the early phase of an event, ischemia may be present before enough injured-cell troponin has reached the blood to exceed that assay’s threshold. High-sensitivity assays can detect injury earlier than conventional assays, but a sample taken soon after symptom onset can still be nondiagnostic.
A normal early result therefore cannot overrule a convincing STEMI ECG. Waiting for a repeat sample while an occluded or critically underperfused artery continues to injure myocardium reverses the proper sequence: the test is being used as a gate to a time-sensitive action it was not designed to delay.
| Test or finding | What it helps establish | What it does not establish alone |
|---|---|---|
| ECG with a STEMI pattern and compatible symptoms | The need for urgent STEMI-pathway assessment and reperfusion | The exact culprit artery or completed myocardial necrosis |
| One early troponin result | Whether measurable myocardial injury is present in that sample | That an early negative result excludes evolving MI, or that a positive result identifies its cause |
| Serial troponin results | Whether injury is acute and how the biomarker changes over time | Permission to delay reperfusion when the ECG already establishes the STEMI pathway |
Keep the treatment decision separate from formal MI confirmation
The 2026 Universal Definition of MI distinguishes acute myocardial injury from infarction. Acute injury is supported by a rise or fall in troponin, with at least one value above the assay’s sex-specific 99th-percentile upper reference limit. To diagnose MI, that acute injury must also occur with evidence of myocardial ischemia, such as ischemic symptoms or new ischemic ECG changes.
This distinction prevents two opposite errors. First, a normal first troponin does not make a clear, early STEMI ECG safe to observe while awaiting serial testing. Second, a positive troponin is not itself proof of a type 1 coronary infarction: myocardial injury can occur in other clinical settings, so the clinical context still matters.
For patients with a nondiagnostic ECG, serial ECGs and an assay-specific troponin pathway help clarify the diagnosis. That is a different branch from a qualifying STEMI pattern. Do not apply a rule-out pathway for an initially nondiagnostic ECG to a patient whose ECG already calls for emergency reperfusion.
Move quickly without treating every ST elevation as STEMI
The rule is not “ST elevation always means thrombotic occlusion.” Check that the tracing is technically sound, confirm the J-point and lead distribution, and compare with an older ECG if one is immediately available. Consider whether the history or tracing suggests a competing diagnosis that would change immediate management. These checks refine the decision; routine additional testing should not delay reperfusion when the STEMI diagnosis is clear.
Obtain troponin promptly, but do so alongside—not ahead of—the urgent response. Communicate symptom timing and ECG findings, activate the appropriate team, and select the reperfusion strategy according to PCI access, anticipated delay, symptom duration, and contraindications. If the ECG is uncertain, symptoms persist or recur, or the patient deteriorates, repeat the ECG and get urgent expert review. The point is not to stop gathering data; it is to avoid making a lagging biomarker the bottleneck.
Practical takeaways
- With compatible ischemic symptoms and a qualifying STEMI ECG, do not wait for troponin before activating reperfusion.
- A normal early troponin can reflect timing; it does not exclude an evolving infarction.
- Troponin supports the formal diagnosis of acute myocardial injury and MI, but it is not a prerequisite for the initial STEMI response.
- Use serial ECGs and assay-specific troponin testing when the ECG is nondiagnostic—not as a reason to delay action on a clear STEMI pattern.
- Check for technical problems and important mimics without turning routine diagnostic workup into a reperfusion delay.
